Form 4: IGM Biosciences Director Felix Baker Receives Equity Compensation in Lieu of Fees

Baker Bros. Advisors LP and affiliated entities reported that IGM Biosciences, Inc. director Felix J. Baker received 953 restricted stock units as compensation for his board service.

Summary

• Felix J. Baker, a director of IGM Biosciences, Inc. (IGMS) and managing member of Baker Bros. Advisors (GP) LLC, acquired 953 restricted stock units (RSUs) of IGMS common stock.
• The RSUs were issued on June 30, 2025, in lieu of $11,500 in director retainer fees, consistent with the Issuer's Outside Director Compensation Policy.
• The 953 RSUs are fully vested upon issuance.
• Baker Bros. Advisors LP, 667, L.P., Baker Brothers Life Sciences LP, Felix Baker, Julian Baker, and Baker Bros. Advisors (GP) LLC are listed as reporting persons, identified as both Director and 10% Owner.
• Following this transaction, the indirect beneficial ownership for 667, L.P. is 357,048 shares and for Baker Brothers Life Sciences LP is 3,763,362 shares.
• Julian C. Baker and Felix J. Baker hold an indirect pecuniary interest in these securities through their ownership in various Baker Bros. entities.
• Baker Bros. Advisors LP maintains complete and unlimited discretion and authority over the investment and voting power of the securities held by the Funds.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. It's a routine disclosure of director compensation in stock, which aligns interests. No negative implications are present, but it's not a major positive catalyst either.

Positives

• Director Felix J. Baker received compensation in company stock, which aligns his financial interests with those of the shareholders.
• The restricted stock units are fully vested upon issuance, providing immediate ownership to the recipient.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which primarily reports an insider transaction.

Management Comments

• Felix J. Baker serves on the Issuer's board of directors as a representative of 667, L.P. and Baker Brothers Life Sciences, L.P. and their affiliates and control persons.
• Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein.
• Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board... and the Funds are entitled to an indirect proportionate pecuniary interest in the Stock Options and RSUs.
• By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer.

Industry Context

This Form 4 filing details a routine compensation event for a director of a biotechnology company. It does not provide broader industry context or trends, focusing solely on the insider transaction.

Corporate Governance

Related Party Transactions

• Felix J. Baker, a director of IGM Biosciences, Inc. and managing member of Baker Bros. Advisors (GP) LLC, received 953 restricted stock units as compensation.
• The transaction involves Baker Bros. Advisors LP and its affiliated entities (667, L.P., Baker Brothers Life Sciences LP, Julian C. Baker, Felix J. Baker, and Baker Bros. Advisors (GP) LLC) who are also 10% owners and have representatives on the board, making this a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of stock as director compensation aligns the director's financial interests with those of the shareholders, potentially fostering long-term value creation. It also represents a minor dilution from the issuance of new shares.
• Management/Directors: Felix J. Baker receives equity compensation, which is a standard practice for incentivizing directors.

Key Dates

Keywords

IGM Biosciences, IGMS, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, RSUs, Baker Bros. Advisors, Felix J. Baker, Stock Ownership, Biotechnology